SOPHiA GENETICS Q3 2026 net loss widens to USD 20.27 million; revenue rises 25% to USD 24.27 million
SOPH•SOPHiA GENETICS’ third-quarter 2026 net loss widened to USD 20.27 million, while revenue rose 25% year over year to USD 24.27 million. The company expects full-year revenue at the upper end of its USD 94 million–USD 96 million guidance range.
1. Quarterly results
SOPHiA GENETICS reported a third-quarter 2026 net loss of USD 20.27 million and revenue of USD 24.27 million, up 25% year over year. It signed 30 new core genomics customers and closed three material BioPharma deals. The company expects full-year 2026 revenue at the upper end of its previously issued USD 94 million–USD 96 million guidance range.
